WRF
BMRN icon

Waddell & Reed Financial’s BioMarin Pharmaceuticals BMRN Stock Holding History

Waddell & Reed Financial’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-25,000
Closed -$2.27M – 527
2017
Q2 		$2.27M Hold
25,000
– – 0.01% 510
2017
Q1 		$2.19M Buy
+25,000
New +$2.22M ﹤0.01% 517

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Waddell & Reed Financial's BMRN Position: Q3 2019 in Review

Waddell & Reed Financial sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 762,764 shares — an estimated $65.3M sold.

Waddell & Reed Financial first reported a position in BMRN in Q4 2013 and held it in 23 quarters. The position peaked at $314M in Q2 2018. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Waddell & Reed Financial reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Waddell & Reed Financial sold 762,764 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $65.3M.
  • Waddell & Reed Financial first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 23 quarters.
  • Waddell & Reed Financial's BioMarin Pharmaceuticals position peaked at $314M in Q2 2018.
  • 437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Waddell & Reed Financial's 13F filing for Q3 2019, filed 14 Nov 2019.